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Abstract
Background: Discovery of cancer drivers is a major goal of cancer research. Driver genes and pathways are often
predicted using mutation frequency, assuming that statistically significant recurrence of specific somatic
mutations across independent samples indicates their importance in cancer. However, many mutations, including
known cancer drivers, are not observed at high frequency. Fortunately, abundant information is available about
functional “active sites” in proteins that can be integrated with mutations to predict cancer driver genes, even
based on low frequency mutations. Further, considering active site information predicts detailed biochemical
mechanisms impacted by the mutations. Post-translational modifications (PTMs) are active sites that are
regulatory switches in proteins and pathways. We analyzed acetylation and ubiquitination, two important PTM
types often involved in chromatin organization and protein degradation, to find proteins that are significantly
affected by tumor somatic mutations.
Methods: We performed computational analyses of acetylation and ubiquitination sites in a pan-cancer dataset
of 3200 tumor samples from The Cancer Genome Atlas (TCGA). These analyses were targeted at different levels of
biological organization including individual genes, pathway annotated gene sets, and protein-protein interaction
networks.
Results: Acetylation and ubiquitination site mutations are enriched in cancer with significantly stronger
evolutionary conservation and accumulation in protein domains. Gene-focused analysis with the ActiveDriver
method reveals significant co-occurrences of acetylation and ubiquitination PTMs and mutation hotspots in
known oncoproteins (TP53, AKT1, IDH1) and highlights candidate cancer driver genes with PTM-related
mechanisms (e.g. several histone proteins and the splicing factor SF3B1). Pathway analysis shows that PTM
mutations in acetylation and ubiquitination sites accumulate in cancer-related processes such as cell cycle,
apoptosis, chromatin regulation, and metabolism. Integrated mutation analysis of clinical information and protein
interaction networks suggests that many PTM-specific mutations associate with decreased patient survival.
Conclusions: Mutation analysis of acetylation and ubiquitination PTM sites reveals their importance in cancer. As
PTM networks are increasingly mapped and related enzymes are often druggable, deeper investigation of specific
associated mutations may lead to the discovery of treatment-relevant cellular mechanisms.
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Background
Cancer is a complex, heterogeneous class of diseases with
the highest mortality in the developed world. Cancer is
driven by molecular alterations that activate oncogenes
and inhibit tumor suppressor genes. These cancer driver
events modify cellular pathways and provide cells with
selective advantages such as uncontrolled growth, sup-
pressed apoptosis, replicative immortality, and mobility
[1]. Different classes of driver modifications are recog-
nized, including chromosomal copy number alterations
[2], epigenetic modifications in DNA methylation [3] and
chromatin state [4], and DNA mutations such as short
insertions-deletions and single nucleotide variants (SNVs).
SNVs are abundant mutations that are reliably detected in
paired sequencing of germline and tumor DNA. The
Cancer Genome Atlas (TCGA) and the International
Cancer Genome Consortium (ICGC) compile compre-
hensive molecular profiles of cancer genomes, tran-
scriptomes, and epigenomes for many tumor types [5, 6].
Integrative analysis of these profiles can provide insights
into tumor biology and support the development of can-
cer therapies.
Discovering drivers of tumor-specific phenotypes is an
important goal of cancer genomics [6]. Driver genes are
challenging to find, as tumor genomes also contain abun-
dant functionally neutral passenger mutations acquired as
a result of genome instability. It is estimated that a typical
solid tumor carries 2–8 driver mutations and ten times
more passengers [7]. Analysis of positive selection as-
sumes that frequent recurrence of a particular mutation in
independent patient samples is statistically unlikely and
therefore indicates a cancer driver. Tools such as MutSig
and MuSic predict genes where observed mutations sig-
nificantly exceed expected genome-wide mutation rates
[8, 9]. Such approaches are complicated by mutational
heterogeneity, as mutation rates vary across genes, and
nucleotide signatures [8, 10, 11], and are influenced by
factors such as gene expression intensity [12], DNA
replication timing [13], and chromatin organization
[14]. Further, frequency-based methods do not provide
corresponding mechanistic hypotheses to explain the
functional consequence of a mutation.
We hypothesize that many functional cancer mutations
alter protein-protein interaction networks and associated
biochemical mechanisms [15]. Post-translational modifica-
tions (PTMs) are chemical alterations of amino acids
(AAs) that act as regulatory switches, extending the func-
tional repertoire of proteins and regulating protein inter-
actions in cell-signaling networks [16]. Thus, specific
mutations in PTM sites may alter networks and lead to
changes in cellular phenotype involved in disease develop-
ment. We recently developed ActiveDriver, a site-specific
mutation enrichment model that highlights cancer genes
with significant co-occurrence of missense mutations and
PTM sites [17]. ActiveDriver assumes that many inde-
pendent mutations in patient tumors are unlikely to co-
occur in PTM sites of the protein unless these sites are
important for the protein’s function in cancer. In estimat-
ing mutation significance, ActiveDriver uses a Poisson
regression model that accounts for multiple factors in-
cluding protein disorder, direct and flanking PTM resi-
dues, and site density. ActiveDriver compares substitution
rates in individual proteins with substitutions in their
active sites and thus provides complementary informa-
tion to traditional genome-wide mutation models. Our
previous analyses of phosphorylation-related mutations
predicted novel cancer genes and pathways, mechanis-
tic hypotheses of mutation function, and found significant
clinical correlations [17–19]. Site-specific mutation ana-
lysis is thus a viable strategy to discover putative cancer
driver genes and hypothesize how they biochemically
function to drive cancer.
Here we focus on acetylation and ubiquitination, two
PTMs of lysine (K) residues. These are the best-
characterized PTMs after phosphorylation and abun-
dant experimental data are available for human proteins
[20–22]. Acetylation and ubiquitination involve distinct
electro-chemical mechanisms and biological roles, and
their co-occurrence on lysines leads to cross-talk and
combinatorial switches of PTMs [23]. Moreover, PTM
sites have a tendency to cluster in protein sequence,
and mutations in regions with highly overlapping PTM
sites create the potential for mutations to target mul-
tiple sites [24]. Here we refer to ubiquitination and
acetylation as lysine PTMs or PTMs unless otherwise
indicated.
Acetylation is the reversible addition of acetyl groups
to lysines conducted by two families of enzymes, acetyl-
transferases (HATs), and deacetylases (HDACs). Acetyl-
ation is primarily associated with chromatin regulation.
The histone code of PTMs determines DNA packaging,
resulting in open or closed chromatin conformations
and modulation of gene expression [25]. Specific histone
modifications and cancer mutations are associated with
silencing of tumor suppressor genes and cancer pro-
gression [26, 27]. Growing evidence indicates that non-
histone proteins, in particular transcription factors, are
subject to acetylation [28]. Acetylation is increasingly
clinically targetable, as pharmaceutical inhibition of
HDAC enzymes for cancer therapy has been subject to
recent clinical trials [29].
Ubiquitination is the addition of ubiquitin peptides to
lysines coordinated by ubiquitin ligases and related en-
zymes. This PTM is canonically the signal of proteasomal
degradation, although other roles are known [30, 31].
Ubiquitination is implicated in many processes, including
receptor endocytosis, proteolysis, protein trafficking, in-
flammation, translation, and DNA repair. Ubiquitination
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also occurs in histones and interacts with other PTMs
of the histone code [25]. It is implicated in tumor de-
velopment and the ubiquitin pathway is an emerging
drug target [32].
As lysine PTMs are involved in cancer-related pro-
cesses, we hypothesize that corresponding signaling
networks are altered in cancer cells by specific mutations
in enzymes and substrate sites. Two recent studies sur-
veyed the pan-cancer mutational landscape of epigenetic
regulators [33, 34]; however, no comprehensive analysis of
cancer mutations affecting acetylation and ubiquitination
sites is available. Thus, we collected cancer mutations in
acetylation and ubiquitination sites and examined their
proteome-wide properties and occurrence in cancer driver
genes, pathways, and molecular interaction networks. As
these PTMs are prospective targets in drug development,
this information helps discover cancer driver mechanisms
with testable hypotheses of pharmacological modulation.
Methods
Post-translational modifications and cancer mutations
Acetylation and ubiquitination sites for human proteins
were retrieved from the PhosphoSitePlus database (re-
trieved 2013-05-23) [22] and filtered to only keep data
from peer-reviewed publications. PTM sites defined as
15-mer AA sequences were mapped exactly to 18,671
high confidence sequences of longest protein isoforms
of the Consensus Coding Sequence (CCDS) database.
Sites with multiple matches per protein were considered,
while partially mapping sites were discarded. Shared PTM
sites comprised sites where central lysines associated with
both acetylation and ubiquitination.
We retrieved the pre-processed pan-cancer dataset of
somatic mutations in 3185 tumor samples curated by
the TCGA for 12 different cancer types [5, 35] from the
Synapse repository (ID syn1729383). We removed 91
hyper-mutated samples with an extreme number of muta-
tions. Chromosomal coordinates of mutations were con-
verted to protein-level substitutions using the Annovar
software [36] and filtered for the longest isoforms defined
above. We only considered non-synonymous missense
SNVs and discarded all other types including nonsense,
silent, insertion/deletion, and non-coding mutations.
Selection, conservation, and domain associations of PTM
site mutations
Positive selection of PTM sites in cancer genomes was
evaluated separately for acetylation and ubiquitination
sites. We compared observed and expected numbers of
mutations in PTM-associated and non-associated protein
sequences and computed significance with one-sided
bootstrap tests with 100,000 shuffles per test. For both
types of PTMs, we only focused on proteins with these
modifications and discarded other non-modified proteins.
Protein domain information for the CCDS sequences
was retrieved from the databases Pfam [37] and SMART
[38]. Disordered sequence regions of proteins were pre-
dicted with the DISOPRED2 software [39] using default
parameters (Additional file 1). Domain-associated and
non-domain sequence regions were assessed for PTM-
related and non-related mutations, and expected distri-
butions of mutation rates were derived by resampling
of sequence residues. Mutation rates of domain and
non-domain regions were tested with the non-parametric
one-sided bootstrap tests with 100,000 shuffles per test.
Protein sequence conservation corresponds to phast-
Cons 46-way scores [40] derived from the Annovar
software. We compared conservation scores of mutated
AAs in PTM-related and non-PTM sequence separately
for disordered and structured protein sequences with the
non-parametric one-sided bootstrap test with 100,000
shuffles per test.
ActiveDriver analysis of PTM mutations and recurrently
mutated sites
Cancer mutations were mapped to PTM sites and PTM-
specific significance scores of genes were computed with
the ActiveDriver software [17]. Mutations were classified
by their proximity to central lysine residues, into three
categories: (1) direct mutations on the central lysine; (2)
proximal mutations within 1–2 residues of the central ly-
sine; and (3) distal mutations within 3–7 residues of the
central lysine, as defined by the default settings of Active-
Driver. Mutational significance was estimated across all
cancer samples of 12 types. Genes with false discovery rate
(FDR) p <0.05 were considered significant. We used the
OncoDriveClust method [41] to assess clustering of muta-
tions in all genes including results from ActiveDriver,
using the recommended settings for TCGA data from
OncoDriveClust documentation. To estimate the signifi-
cance of known cancer genes in ActiveDriver results, we
implemented a custom permutation test with mutation
frequency of genes. In brief, we binned all genes into 100
groups according to mutation frequency and then sam-
pled the number of genes detected by ActiveDriver, ac-
cording to the expected mutation frequency distribution
of known cancer genes. We estimated an empirical p value
from 10 million permutations relative to the number of
cancer genes detected in ActiveDriver results according to
the Cancer Gene Census database [42].
Pathway analysis of PTM mutations and Enrichment Map
Pathway analysis was performed using functional anno-
tations from the Gene Ontology [43], and the databases
of Reactome [44] and CORUM [45], retrieved from the
g:Profiler webserver [46]. The protein sets were filtered
to discard small (≤2 proteins) and large lists (>1000
proteins). Only annotations of biological processes of
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the Gene Ontology were used. Pathway analysis consid-
ered proteins with PTM sites while non-modified proteins
were discarded. Each gene list corresponding to a pathway
or process was tested separately with a Poisson exact test.
Observed protein sequence length and associated muta-
tions of PTM sites of protein sets were compared with the
expected mutation rate of all pathway-associated protein
sequence. Protein sets with fewer than two separately mu-
tated proteins were discarded to avoid results from single
cancer drivers. Pathways with an FDR-corrected p value
<0.05 were considered significant. Pathways were visual-
ized using the Enrichment Map app [47] of the Cytoscape
software [48] that visualizes enrichment analysis results as
a network with nodes representing pathways and edges
connecting pathways with many shared genes. Singleton
nodes and small and redundant groups of up to eight
nodes were discarded for simplicity and the remaining
sub-networks were manually curated and assigned the
most representative functional annotations.
HyperModules analysis of protein networks and patient
survival information
To analyze patient survival information associated with
PTM mutations, we constructed a PTM-specific inter-
action network of human proteins from the BioGRID
database [49]. We selected physical protein-protein
interactions between proteins with PTM sites and pro-
teins annotated as PTM enzymes. Interactions for acetyl-
ation and ubiquitination were compiled separately. PTM
enzymes were curated from three resources: the Gene
Ontology [43], the hUbiquitome database [50], and the
Compendium of Protein Lysine Acetylation (CPLA) [20].
Survival information of patients profiled by the TCGA
were retrieved from the study by Kandoth et al. [51].
Patients with each type of cancer were analyzed separately.
Survival-associated network modules were predicted with
the Cytoscape implementation of the HyperModules algo-
rithm [52]. HyperModules is a greedy method to find
maximally survival-correlated modules that uses a log-
rank test to evaluate significance of survival correlations.
The modules were additionally filtered after expected dis-
tributions of p values were computed from 100 network-
shuffling permutations. Modules with empirical p <0.05
from permutation tests were considered significant.
Results
Acetylation and ubiquitination sites are altered by
thousands of cancer mutations
To characterize cancer mutations in acetylation and ubi-
quitination sites, we collected experimentally determined
sites in human proteins from the PhosphoSitePlus data-
base [22]. We retrieved 29,933 sites in 7167 proteins, in-
cluding 7480 acetylation sites, 25,773 ubiquitination sites,
and 3280 sites targeted by both PTMs. We included
fourteen (± seven) residues of flanking sequence around
PTM sites and merged regions of overlapping PTM se-
quence. Flanking sequence affects interactions of sub-
strates and PTM enzymes in phosphorylation [53] and
acetylation [54]; however, less is known about the speci-
ficity of ubiquitination enzymes. Flanking sequence also
associates with short linear motifs and PTM cross-talk,
potentially altered by mutations in cancer.
We integrated PTM sites with cancer mutations,
using the dataset of 241,701 somatic missense SNVs in
3185 tumor samples of the TCGA pan-cancer project
comprising 12 cancer types including brain, colon, and
lung cancer [5]. For each tumor sample the TCGA pro-
vided a normal blood (or tissue) sample to serve as a
control [5]. We found 2106 acetylation-related SNVs,
6405 ubiquitination-related SNVs, and 883 SNVs in
shared sites of the two PTMs, covering 72 % of cancer
samples (Additional files 2 and 3). When considering
only lysine residues, there are a total of 8381 SNVs of
which 599 are associated with PTM sites. PTM muta-
tions replacing the central lysine residues are most
likely to disrupt PTMs and we refer to these as direct
mutations. The majority of mutations occur in flanking
sequence of PTMs and potentially affect protein modi-
fication indirectly through enzyme sequence specificity
and local structural environment.
Lysine PTM sites are enriched in cancer mutations with
high conservation and functional impact
We studied proteome-wide properties of PTM-related
cancer mutations to evaluate their global functional im-
portance in cancer. We focused on proteins with at
least one PTM site and removed non-modified proteins
to avoid systematic biases. First, we examined substitu-
tion rates in ubiquitination and acetylation sites (including
their ±7 flanking region) in comparison to non-PTM se-
quence. We found that acetylation sites are enriched in
cancer mutations (fold change [FC] = 1.12, p = 2.2 × 10–4,
bootstrap test) while ubiquitination PTM sites show no
significant difference in mutational frequency (FC = 0.98,
p = 0.12, Fig. 1a). In addition, we studied rates of substitu-
tion for the central modified lysine residues with non-
modified lysines, and found that substitutions of central
PTM residues are more frequent than expected (FC =
1.21, p = 2.9 × 10–2 for acetylation; FC = 1.13, p = 6.0 ×
10–3 for ubiquitination). This suggests that rewiring of
lysine PTMs is important in cancer and this is not an
artefact of codon structure. Interestingly, proteins with ly-
sine PTMs are generally less mutated than non-modified
proteins (FC = 0.85, p <1 × 10–5), suggesting that modified
proteins are more sensitive to mutations. However, PTM
proteins also show higher expression in the TCGA pan-
cancer dataset (mean expression FC = 4.00, p <10–300,
Wilcoxon test). Hence their lower mutation frequency
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may be also explained by transcription-coupled DNA re-
pair [12]. In summary, mutations in lysine PTM sites are
positively selected in cancer genomes and therefore are
functionally important.
Second, we examined the functional impact of PTM-
related mutations relative to protein domains and dis-
ordered sequence. SNVs in acetylation and ubiquitina-
tion sites are significantly concentrated in protein
domains, suggesting that many PTM-associated substi-
tutions directly impact protein structure and activity
(FC = 1.15, p <1 × 10–5, bootstrap test). Analysis of disor-
dered sequence predictions from DISOPRED2 software
[39] shows that ubiquitination sites are enriched in struc-
tured regions (FC = 1.17, p <10–300, Fisher’s test), while
acetylation sites are evenly distributed in structured and
disordered sequence (Fig. 1b). In contrast, phosphoryl-
ation sites are primarily found in disordered regions [18].
Thus PTMs differ in their preferences toward protein
structure and their mutational impact needs to be ana-
lyzed separately due to differences in background muta-
tion distributions. The most frequently PTM-mutated
protein domains include histones, the DNA-binding do-
main of TP53, and domains of unknown function associ-
ated with regulatory genes such as the DUF902 domain in
the histone acetyltransferase EP300 [55]. Thus lysine PTM
mutations may modulate protein function through regula-
tory switches in structured domains.
Third, we studied evolutionary sequence conserva-
tion of PTM-associated mutations relative to other
missense mutations using phastCons 46-way gene con-
servation scores. SNVs found within lysine PTM sites
(including ±7 flanking residues) target residues are
more strongly conserved than those of non-PTM SNVs
(FC = 1.08, p <1 × 10–5, bootstrap test, Fig. 1c). This re-
lationship holds when separating SNVs into disordered
and structured sequences (FC = 1.04, p <1 × 10–5; and
FC = 1.09, p <1 × 10–5, respectively). We also scored
PTM-related mutations by integrating results from five
predictors of variant function (SIFT [56], PolyPhen2
[57], LRT [58], PhyloP [59], MutationTaster [60]), as
collected by the Annovar software [36]. We scored
each SNV on a 0 to 5 scale by counting the methods
that consider that variant deleterious according to
thresholds curated by the dbNSFP database [61]. SNVs
found within PTM sites are predicted to be deleterious
more often than other missense SNVs (Fig. 1d). This
difference is most evident in high-impact mutations
with consensus predictions from all five tools (odds
ratio = 1.52, p = 4.6 × 10–17, Fisher’s exact test).
Together, the three observations suggest positive selec-
tion and functional importance of PTM-related mutations
in cancer genomes. As ubiquitination and acetylation
regulate core processes such as protein degradation and
chromatin state, mutations in PTM sites may rewire sig-
naling networks, leading to altered phenotypes important
in cancer development.
ActiveDriver highlights known and candidate cancer
genes with PTM-specific mutations
To better understand the distribution and function of
PTM mutations in cancer genes, we utilized the Active-
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Fig. 1 Importance of cancer mutations in post-translational modification (PTM) sites of acetylation and ubiquitination. a Cancer mutations in
protein acetylation sites are significantly more frequent than non-modified protein sequence, while ubiquitination sites show expected mutation
rates. PTM sites include central lysine residues and ±7 flanking windows. Comparisons only include proteins with respective PTM sites. b Ubiquitination
sites are enriched in protein sequences associated with structured regions, while acetylation sites are evenly distributed among structured and
disordered regions. c PTM-associated cancer mutations show greater evolutionary conservation than non-PTM mutations. Disordered and
structured protein sequences are compared separately. d PTM-associated cancer mutations are more frequently predicted deleterious by an
ensemble of five variant function predictors
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identifies genes enriched in PTM-specific mutations using
a Poisson regression model that estimates mutational sig-
nificance from protein disorder, direct and flanking PTM
residues, and site density.
Composite analysis of 12 cancer types revealed 43 genes
with significant enrichment of PTM-specific SNVs (p <0.05,
Fig. 2a, Additional file 4). Ten genes are confirmed cancer
drivers according to the Cancer Gene Census database [62]
(p = 2.0 × 10–7, custom permutation test), suggesting that
mutations in these cancer genes involve alterations of PTM
networks. For example, the metabolic enzyme IDH1 carries
36 mutations in residue R132 of the catalytic domain caus-
ing altered enzymatic activity and histone demethylation
[62, 63]. Our analysis associates these mutations to PTM
sites (p = 4.47 × 10–3 from ActiveDriver) as IDH1 is ubiqui-
tinated at K126. This oncogene may be regulated by a com-
binatorial PTM mechanism as the hotspot also overlaps


































































































































































































































































































































































































Fig. 2 Cancer genes with significant mutations in PTM sites. a ActiveDriver predicts cancer driver genes with significant co-occurrence of PTM
sites and mutations. Genes are ranked by statistical significance. Known PTM enzymes associated with mutated PTM sites are shown on top of
bars. Known cancer genes are highlighted in boldface. Combinatorial mutations shown in green affect lysines that are both acetylated and
ubiquitinated. b PTM-associated sequence regions with recurrent cancer mutations (more than five SNVs). Sequence coordinates are shown
on top of bars. Known cancer genes are highlighted in boldface. Mutations shown in orange are adjacent to both acetylation and ubiquitination sites.
c Cancer mutations in splicing factor subunit SF3B1 (top panel) significantly associate with PTM sites (bottom panel). The ubiquitination site K700 is
disrupted by the recurrent cancer mutation K700E
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site at Y139 [18]. The gene with the most significant p value
in the list is the phosphatase PTEN, where a mutation hot-
spot at R130 disrupts the active pocket of the phosphatase
and the arginine required for catalytic activity [64]. Active-
Driver highlights this mutation due to acetylation sites
K125 and K128 targeted by the acetyltransferase PCAF
(KAT2B); acetylation at these sites are associated with de-
creased PTEN activity [65]. The ActiveDriver gene list also
includes histones as well as PTM-related enzymes like
kinases and acetyltransferases. Pathway analysis with g:Pro-
filer [46] shows significant enrichment of several processes,
including DNA binding (p = 5.0 × 10–6), cell cycle regula-
tion (p = 5.9 × 10–3), and metabolism (p = 6.3 × 10–3).
To investigate if our analyses could be due simply to
mutation clustering, we analyzed clustering of mutations
across all genes using OncoDriveClust [41], and found
that three of 43 genes from ActiveDriver analysis exhibited
statistically significant mutation clustering (IDH1 p =
1.2 × 10–8, PTEN p = 6.0 × 10–4, and AKT1 p = 5.1 × 10–9).
Thus, most of the genes ActiveDriver finds are not ex-
plained by mutation clustering. We also asked how
many of our results depend on our flanking region def-
inition and repeated ActiveDriver analysis by only focus-
ing on central modified lysines. We found six significant
genes (SF3B1, AHNAK, TP53, MAP2K1, PYGL, ATPIF1;
FDR p <0.05), five of which are found in our analyses of
ActiveDriver and mutation recurrence.
Several PTM substrates highlighted by our analysis are
associated with well-studied enzymes, such as EP300,
TRAF, and PCAF, for which pharmacological inhibitors
are increasingly available. Enrichment of known cancer
genes and pathways validates our results. Follow-up ex-
periments will be required to confirm these findings, as
ActiveDriver is primarily a hypothesis generation tool
that integrates functional information with mutations in
known and candidate cancer genes. Site-specific interac-
tions with PTM enzymes are still relatively unmapped,
but better characterization of these networks may lead
to discovery of new druggable targets with cancer spe-
cific mutations.
Most frequent PTM-associated mutations involve TP53,
the AKT1 kinase, and the histone HIST1H3B
Next, we analyzed PTM sites with the most frequent
mutations in the pan-cancer dataset. We retrieved con-
tinuous PTM-related sequence regions and annotated
these to cancer types, PTM classes, and upstream en-
zymes. This approach is complementary to ActiveDriver
as it also highlights proteins that are likely not found by
ActiveDriver due to lack of PTM-specific mutational en-
richment. These may include short proteins with relatively
large PTM regions and frequently mutated genes with al-
terations within and outside PTM regions. However, these
genes are likely important in cancer due to frequent
mutations.
We found 25 distinct PTM-associated mutation hot-
spots with more than five SNVs, including frequently
mutated cancer driver genes such as TP53 (AA 113-
146, n = 73) and IDH1 (AA 119-133, n = 65) (Fig. 2b).
Some PTM sites are also substrates of cancer-related
epigenetic enzymes such as EP300 and KAT2B. These
genes include several cases that provide proof-of-
principle of our hypothesis of PTM mutations in can-
cer. One well-studied example occurs in TP53 where
17 cancer samples of primarily breast and colorectal
cancer have SNVs affecting residue K120. This residue
is a combinatorial PTM site with evidence of acetyl-
ation and ubiquitination, and a substrate site of the ace-
tyltransferase KAT8, important during DNA damage
response. Disruption of this PTM through KAT8
knockout or K120 mutagenesis leads to loss of TP53
mediated apoptosis [66]. Another well-studied cancer
mutation we identify is the substitution E17K in AKT1
(PKB) kinase of the PI3K pathway, observed across 20
samples including 18 breast tumors. This mutation cre-
ates a ubiquitination site targeted by the ubiquitin lig-
ase TRAF upstream of the ubiquitination site K14. This
site has been found to be readily ubiquitinated, promot-
ing membrane localization and over-activation of the
oncoprotein AKT1 [67, 68]. Lastly, our analysis high-
lights the histone site H3.3-K27, which was recently
identified to undergo K27M mutation in rare and rapid
onset pediatric brain cancers [69]. In normally func-
tioning cells, methylation at H3K27 has been associated
with reduced gene expression. Acetylation at H3K27 is
believed to be antagonistic to H3K27 methylation and
has been associated with increased gene expression.
K27M substitutions at this site cause global reduction
in the repressive histone mark of trimethylation
(H3K27me3), increasing gene expression and promot-
ing tumorigenesis [70]. We observe mutations in eight
samples targeting the K27 site across the HIST1H3
gene family, primarily within uterine carcinoma samples.
Thus, several recurrent cancer mutations we identify are
already confirmed in the literature to be functionally
related to lysine PTMs, supporting our list of candidate
genes.
Mutations in splicing factor subunit SF3B1 associate with
disrupted ubiquitination
SF3B1 is the second most significant gene with PTM-
specific cancer mutations (FDR p = 3.2 × 10–6 from
ActiveDriver, Fig. 2c). While the function of SF3B1 in
cancer is not well established, its mutations are fre-
quently observed in myelodysplastic syndromes [71].
The gene is involved in pre-mRNA processing and spli-
cing, as it encodes subunits of the U2 small nuclear
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ribonucleoprotein (snRNP) complex and the minor
spliceosome complex. Our analysis highlights a recur-
rent K700E substitution found in nine breast cancer
samples that replaces a central ubiquitinated lysine and
thus disrupts modification of the protein at that site.
Individual mutations are also found near other ubiquiti-
nation sites of SF3B1 (K182, K333, K785), suggesting
that altered ubiquitination of the protein is important
in cancer.
While little is known about the specific role of ubiquiti-
nation of SF3B1 at K700, this PTM type is involved in
spliceosome assembly and function. Ubiquitination medi-
ates protein-protein interactions of snRNP complexes
[72], and replacement of wild-type ubiquitin with a non-
functional mutant ubiquitin disrupts spliceosome assem-
bly and leads to decreased mRNA splicing [73]. Multiple
alignment analysis of homologous protein domains shows
that the K700E substitution is less deleterious than ran-
domly generated missense mutations [71]. Most cancer
variation in SF3B1 in the TCGA dataset involves missense
mutations, while stop codon and frame-shift mutations
are not seen. The two observations suggest that the
ubiquitination-associated mutation K700E in SF3B1 may
change protein function while retaining protein structure.
Further, Maguire et al. recently showed that K700E muta-
tions likely affect splicing in breast tumors [74]. We
propose that loss of ubiquitination at K700 in SF3B1 leads
to altered spliceosome assembly and causes aberrant spli-
cing in cancer.
Pathway analysis of PTM mutations highlights specific
metabolic and signaling pathways, chromatin remodeling,
and the APC/C complex
Cancer is driven by alterations of hallmark biological path-
ways that provide cells with selective advantages during
tumor growth [1]. Thus different mutations within the
same pathway can lead to similar functional outcomes. To
discover pathways with frequent PTM-related mutations
and to better interpret rare mutations, we performed a
pathway enrichment analysis. We searched for cellular
processes and protein complexes, represented as gene
sets, that possess unexpectedly high rates of PTM-specific
mutations compared to background missense mutation
rates. We studied biological processes from Gene Ontol-
ogy [43], pathways from Reactome [44], and protein com-
plexes from CORUM [45].
In total, we identified 587 pathways with significant
enrichment of mutations in acetylation and ubiquitina-
tion sites (FDR p <0.05, Poisson test). We visualized these
results as an Enrichment Map [47] and highlighted major
functional themes with the most frequently mutated genes
(Fig. 3). The top 50 statistically significant gene sets
cover cancer hallmark processes including cell adhesion,
PI3K-AKT signaling, apoptosis, cell cycle regulation, and
response to DNA damage. Chromatin remodeling pro-
cesses and histone complexes are also found. Besides
recurrently mutated proteins PTEN, AKT1, and TP53,
representing nearly half of the enriched GO terms, others
with PTM-specific mutations are apparent, such as
MDM2, the ubiquitin ligase involved in TP53 regulation,
CDKN1B, a cyclin-dependent kinase inhibitor, AAMP, an
angiogenesis-associated migratory protein, and multiple
proteins involved in signal transduction (GPS2, HDAC3,
LYN, PPP2CA). The multi-subunit anaphase-promoting
complex (APC/C) involves 35 SNVs related to acetylation
and ubiquitination sites (p = 1.19 × 10–3). APC/C func-
tions as a ubiquitin ligase that blocks mitosis by marking
cell cycle proteins for degradation and its deregulation is
linked to genomic instability in cancer cells [75]. As the
APC/C complex is also regulated by PTMs, we propose
that infrequent cancer mutations in PTM sites drive tu-
mors by deregulating the structure and function of the
complex and impacting cell proliferation pathways.
In summary, pathway analysis of mutations in PTM
sites identifies recurrent and rare mutations that may
affect protein switches in pathways. Deeper investigation
of these findings will help elucidate novel mechanisms of
cancer biology and pharmacologically relevant mutations.
Network analysis reveals survival-associated protein modules
and suggests that PTM-related mutations relate to poor
prognosis
Next, we aimed to characterize PTM-associated mutations
in the context of cancer patient survival. Protein-focused
survival analysis of specific mutations is challenging, as
only few proteins have sufficient mutation frequency to
compare patients with PTM-associated mutations within
cancer types. Thus, we performed a network module sur-
vival analysis using the HyperModules algorithm [52] to
cluster infrequently mutated proteins into connected net-
work modules with higher mutation frequency and signifi-
cant survival associations. The HyperModules algorithm
incorporates a permutation-based control procedure that
performs clustering with survival data on networks with
randomly shuffled mutations to estimate significance of
modules detected in true data. For this analysis, we con-
structed a PTM-specific protein interaction network using
the BioGRID database [49], comprising physical interac-
tions between modified proteins and PTM enzymes such
as acetylases and ubiquitin ligases (Additional file 5).
We carried out HyperModules analyses for 12 cancer
types and identified 132 network modules of proteins
where PTM-specific mutations indicate significant differ-
ences in patient survival (Fig. 4a, FDR p <0.05, permuta-
tion tests, Additional file 6). Interestingly, all but one
module indicate reduced patient survival, suggesting that
certain PTM-associated mutations occur in more aggres-
sive tumors. To examine the individual proteins within
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these partially overlapping and cancer type-specific
modules, we ranked proteins by their frequency of oc-
currence in discovered modules (Fig. 4b). The top pro-
tein SF3B2, with five individual mutations primarily
occurring in ubiquitination sites of lung adenocarcin-
oma patients, is a component of the U2 spliceosome
pathway, suggesting it plays a similar role to the SF3B1
protein described above. Also included are two histone
genes mutated in lung and bladder carcinomas; the
HIST1H1E histone expressed across all somatic tissues,
and the replication-dependent histone HIST3H2BB, as
well as several proteins related to gene expression (p =
3.4 × 10–2), RNA binding (p = 2.18 × 10–3), and ER
protein processing (5 × 10–2). Our network-guided inte-
gration of mutations with patient survival information
helps highlight genes and pathways for study as candi-
date biomarkers. This strategy is useful to interpret sets
of rare mutations that converge on common systems
and pathways.
Mutations in the RNF20-HISTH2BE-HISTH2BJ interaction
module of ubiquitin signaling associated with transcriptional
regulation of proto-oncogenes
One of the top modules from the HyperModules analysis
contains several genes associated with transcriptional
regulation of oncogenes. The module comprises 13 genes
(FBXO11, HECTD1, HIST1H2BJ, HIST2H2BE, NOC2L,
RNF168, RNF20, SET, SUMO1, SUMO2, UBC, YWHAQ,
ZFP91) with 13 PTM-associated mutations distributed








































































Fig. 3 Processes and pathways with frequent cancer mutations in PTM sites. Enrichment Map shows a network of processes and pathways with
over-representation of mutations in acetylation and ubiquitination sites. Nodes represent processes and pathways, and edges connect those with
many common genes. Similar processes are grouped into functional themes and the most frequently mutated genes are highlighted
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gene mutation per patient (Fig. 4c). Survival analysis
shows that mutations in the module associate with
markedly lower survival of patients compared to other
LUAD patients (log-rank p = 3.21 × 10–11, permutation
test p = 0.039, Fig. 4d). The central protein of the module
RNF20 is the major E3 ligase that performs ubiquitination
of H2B histone proteins. While ubiquitination of H2B his-
tones are associated with the transcriptional regulation of
many genes, only a subset of these are regulated by RNF20-
mediated histone ubiquitination [76]. Among these genes
are several oncogenes including MYC and FOS. Further-
more, RNF20 depletion is associated with transcriptional
regulation of cell migration and tumorigenesis [76]. We
hypothesize that mutations affecting this module disrupt
the ubiquitination of H2B substrate level leading to upregu-
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Fig. 4 PTM-associated network modules with patient survival correlations. a Analysis of a large protein-protein interaction network with HyperModules
reveals protein modules where PTM-specific mutations correlate with reduced patient survival. The top 28 modules with lung and brain cancer
mutations are shown. Node size corresponds to the number of PTM mutations per gene. b Survival-linked interaction modules often comprise
overlapping sets of genes. The top 30 genes from modules are shown with colors representing modules discovered for different cancer types.
c Top module of interest comprises 13 PTM-associated mutations in lung cancer. The module is indicated with an asterisk on panel (a). d Lung
cancer patients with mutations in the module of interest have significantly lower survival compared to other lung cancer patients
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Discussion and conclusions
Traditional methods of cancer driver discovery primar-
ily focus on mutational frequency to identify sites of
positive selection. Our approach extends this strategy
by considering prior knowledge about cellular mecha-
nisms. We assume that positive selection in cellular
networks indicates their importance in cancer biology.
This approach gains statistical power by collecting muta-
tions across multiple positions or genes into a network for
input into a single statistical test. By identifying mutations
in protein sites that mediate molecular interactions and
determine protein activation, inhibition, or degradation,
we uncover specific network-related mechanisms that
potentially drive cancer. We also reveal rarely, but site-
specifically, mutated candidate genes hidden among abun-
dant passenger mutations. Our results represent a re-
source of mechanistically detailed hypotheses that can
be experimentally tested to validate cancer driver genes.
Further, the identification of PTM-related enzymes in-
volved in a cancer driver process helps identify ap-
proved and experimental drugs targeting these enzymes
that may be useful cancer treatments, as we previously
showed for the PRC2 complex that methylates histones
in ependymoma [77].
Several considerations limit the interpretation of our
findings. First, as PTMs occur tissue-specifically and are
mostly discovered through high-throughput technologies,
our site collection is incomplete and is expected to con-
tain false positives. Second, some sites and mutations may
be inactive in cancer cells as our analysis only considers
the longest isoform of all proteins. Third, our network
analysis utilizes the entire collection of known interactions
of PTM enzymes and proteins with PTM sites. We do not
consider cellular context such as enzyme activation or co-
localization with substrate proteins, as this information is
generally not available within cancer samples. We instead
rely on identifying signs of positive selection to highlight
important PTMs, but this still may fail for PTMs affected
by a low number of mutations. Fourth, acetylation and
ubiquitination site information is still emerging. As more
data become available, in particular proteome-wide
measurements in cancer genomics efforts, a number of
these limitations will be addressed and we are likely to
discover more cancer mutations with PTM-associated
function. Fifth, as different types of PTM sites are often
clustered in protein sequence, some mutations affecting
lysine PTMs may in fact alter phosphorylation or other
modifications. Lastly, a number of mutant genes identi-
fied by ActiveDriver, such as PTEN, have not been
characterized in the context of PTM-mutations and re-
quire experimental follow-up for validation.
Positive selection of PTM sites in cancer genomes in-
dicates their involvement in cancer-relevant processes.
In the human population, PTM sites undergo specific
negative selection and are enriched in diverse mutations
of inherited disease [24]. These observations emphasize
the importance of PTM sites and associated networks in
physiology, development, and disease. Current approaches
for interpreting missense SNVs largely focus on sequence
conservation, population frequency of variation, and AA
properties of substituted residues [5, 78]. Integration of
PTM data with the above information provides additional
functional evidence not available in traditional methods.
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